- Home
- HKD vs DCTH Comparison
HKD vs DCTH Comparison
Compare HKD & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKD
- DCTH
- Stock Information
- Founded
- HKD 2003
- DCTH 1988
- Country
- HKD France
- DCTH United States
- Employees
- HKD N/A
- DCTH N/A
- Industry
- HKD Finance: Consumer Services
- DCTH Medical/Dental Instruments
- Sector
- HKD Finance
- DCTH Health Care
- Exchange
- HKD Nasdaq
- DCTH Nasdaq
- Market Cap
- HKD 663.1M
- DCTH 630.4M
- IPO Year
- HKD 2022
- DCTH N/A
- Fundamental
- Price
- HKD $2.28
- DCTH $16.59
- Analyst Decision
- HKD
- DCTH Strong Buy
- Analyst Count
- HKD 0
- DCTH 4
- Target Price
- HKD N/A
- DCTH $24.00
- AVG Volume (30 Days)
- HKD 1.0M
- DCTH 610.5K
- Earning Date
- HKD 01-01-0001
- DCTH 05-08-2025
- Dividend Yield
- HKD N/A
- DCTH N/A
- EPS Growth
- HKD 9.93
- DCTH N/A
- EPS
- HKD 0.23
- DCTH N/A
- Revenue
- HKD $20,445,000.00
- DCTH $53,850,000.00
- Revenue This Year
- HKD N/A
- DCTH $141.47
- Revenue Next Year
- HKD N/A
- DCTH $49.31
- P/E Ratio
- HKD $8.98
- DCTH N/A
- Revenue Growth
- HKD N/A
- DCTH 1068.87
- 52 Week Low
- HKD $1.65
- DCTH $6.33
- 52 Week High
- HKD $5.80
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- HKD 48.48
- DCTH 58.15
- Support Level
- HKD $1.93
- DCTH $16.02
- Resistance Level
- HKD $3.44
- DCTH $17.29
- Average True Range (ATR)
- HKD 0.22
- DCTH 0.99
- MACD
- HKD 0.01
- DCTH -0.03
- Stochastic Oscillator
- HKD 9.27
- DCTH 49.63
About HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment, hotel operations, hospitality and VIP services segment and media and entertainment services. The company generates maximum revenue by providing financial digital solutions through its insurance brokerage services and other digital solutions services. Geographically, the company generates maximum revenue from Hong Kong and Singapore.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.